This week, at the 2021 Controlled Release Society Annual Meeting, Dr. Wang did a presentation using gut organoids as a platform for evaluating the delivery of nanoparticles to treat inflammatory bowel disease. The research took advantage of gut organoids as an ex vivo platform to evaluate nanoparticles absorption, distribution, metabolism, and excretion (ADME) screening by gut epithelial cells while focusing on the effect of particle charges. Bioengineered organoids have garnered momentum for their applications in modeling human development and disease, drug screening, and future vaccine design.